- Home
- AEMD vs NCNA Comparison
AEMD vs NCNA Comparison
Compare AEMD & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- NCNA
- Stock Information
- Founded
- AEMD 1984
- NCNA 1997
- Country
- AEMD United States
- NCNA United Kingdom
- Employees
- AEMD N/A
- NCNA N/A
- Industry
- AEMD Medical/Dental Instruments
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- NCNA Health Care
- Exchange
- AEMD Nasdaq
- NCNA Nasdaq
- Market Cap
- AEMD 5.0M
- NCNA 4.7M
- IPO Year
- AEMD N/A
- NCNA 2017
- Fundamental
- Price
- AEMD $0.58
- NCNA $1.22
- Analyst Decision
- AEMD Strong Buy
- NCNA Buy
- Analyst Count
- AEMD 1
- NCNA 2
- Target Price
- AEMD $7.00
- NCNA $25.00
- AVG Volume (30 Days)
- AEMD 6.6M
- NCNA 90.3K
- Earning Date
- AEMD 02-12-2025
- NCNA 11-25-2024
- Dividend Yield
- AEMD N/A
- NCNA N/A
- EPS Growth
- AEMD N/A
- NCNA N/A
- EPS
- AEMD N/A
- NCNA N/A
- Revenue
- AEMD N/A
- NCNA N/A
- Revenue This Year
- AEMD N/A
- NCNA N/A
- Revenue Next Year
- AEMD N/A
- NCNA N/A
- P/E Ratio
- AEMD N/A
- NCNA N/A
- Revenue Growth
- AEMD N/A
- NCNA N/A
- 52 Week Low
- AEMD $0.24
- NCNA $1.17
- 52 Week High
- AEMD $2.35
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- AEMD 57.14
- NCNA 35.87
- Support Level
- AEMD $0.36
- NCNA $1.17
- Resistance Level
- AEMD $0.83
- NCNA $1.31
- Average True Range (ATR)
- AEMD 0.09
- NCNA 0.06
- MACD
- AEMD 0.02
- NCNA 0.02
- Stochastic Oscillator
- AEMD 32.84
- NCNA 22.73
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.